menu

Cases in Acute Kidney Injury: Applications for Clinical Practice

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Cases in Acute Kidney Injury: Applications for Clinical Practice

close
0.25 credits
15 minutes
Cases in Acute Kidney Injury: Applications for Clinical Practice
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
Details
Presenters
Related
Comments
  • Overview

    Acute kidney injury (AKI) is a complication in 10%-15% of patients admitted to the hospital and is even more prevalent in patients in the ICU where the incidence can exceed 50%. Serum creatinine and urine output are traditionally used to define AKI, but these markers are of limited value since they only appear following kidney injury. Early identification of patients at high risk for developing AKI is at the heart of improving AKI outcomes. This task is now clinically feasible with the emergence of predictive biomarkers of kidney stress.

    Join us for this case-based panel discussion highlighting how kidney stress biomarkers can be incorporated into clinical decision-making for patients at high risk for developing AKI.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Sandra L. Kane-Gill, PharmD, MS, FCCM, FCCP
    Professor of Pharmacy and Therapeutics
    University of Pittsburgh School of Pharmacy
    Pittsburgh, PA
    Nothing to disclose.

    Faculty:
    Peter Pickkers, MD, PhD
    Professor of Experimental Intensive Care Medicine
    Radboud University Medical Center
    Nijmegen, The Netherlands
    Consulting Fees: AM-Pharma, SphingoTec

    Alexander Zarbock, MD
    Department of Anesthesiology and Intensive Care Medicine
    University Hospital Münster
    Münster, Germany
    Consulting Fees: A&A, AM-Pharma, Astute Medical, Baxter, bioMérieux, Fresenius, Guard Therapeutics, Novartis, Springer, Ratiopharm
    Contracted Research: Baxter, bioMérieux, Fresenius 

    Reviewers/Content Planners/Authors:

    • Ann Early has nothing to disclose.
    • Barry A. Fiedel, PhD, has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Nick Lombardi has ownership interest with Vertex Pharmaceuticals.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss the use of urinary biomarkers of kidney stress for the early diagnosis of acute kidney injury (AKI) in the critical care setting as well as their use as tools to assess AKI risk
    • Identify opportunities to reduce the incidence of AKI in patients at high risk of the disease
    • Discuss new guidelines regarding the use of biomarker testing to identify AKI in critically ill patients
  • Target Audience

    This activity is designed to meet the educational needs of nephrologists, critical care physicians, surgeons, emergency medicine physicians, nurse practitioners, nurses, physician assistants, and hospital pharmacists.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from bioMérieux.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Acute kidney injury (AKI) is a complication in 10%-15% of patients admitted to the hospital and is even more prevalent in patients in the ICU where the incidence can exceed 50%. Serum creatinine and urine output are traditionally used to define AKI, but these markers are of limited value since they only appear following kidney injury. Early identification of patients at high risk for developing AKI is at the heart of improving AKI outcomes. This task is now clinically feasible with the emergence of predictive biomarkers of kidney stress.

    Join us for this case-based panel discussion highlighting how kidney stress biomarkers can be incorporated into clinical decision-making for patients at high risk for developing AKI.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Sandra L. Kane-Gill, PharmD, MS, FCCM, FCCP
    Professor of Pharmacy and Therapeutics
    University of Pittsburgh School of Pharmacy
    Pittsburgh, PA
    Nothing to disclose.

    Faculty:
    Peter Pickkers, MD, PhD
    Professor of Experimental Intensive Care Medicine
    Radboud University Medical Center
    Nijmegen, The Netherlands
    Consulting Fees: AM-Pharma, SphingoTec

    Alexander Zarbock, MD
    Department of Anesthesiology and Intensive Care Medicine
    University Hospital Münster
    Münster, Germany
    Consulting Fees: A&A, AM-Pharma, Astute Medical, Baxter, bioMérieux, Fresenius, Guard Therapeutics, Novartis, Springer, Ratiopharm
    Contracted Research: Baxter, bioMérieux, Fresenius 

    Reviewers/Content Planners/Authors:

    • Ann Early has nothing to disclose.
    • Barry A. Fiedel, PhD, has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Nick Lombardi has ownership interest with Vertex Pharmaceuticals.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss the use of urinary biomarkers of kidney stress for the early diagnosis of acute kidney injury (AKI) in the critical care setting as well as their use as tools to assess AKI risk
    • Identify opportunities to reduce the incidence of AKI in patients at high risk of the disease
    • Discuss new guidelines regarding the use of biomarker testing to identify AKI in critically ill patients
  • Target Audience

    This activity is designed to meet the educational needs of nephrologists, critical care physicians, surgeons, emergency medicine physicians, nurse practitioners, nurses, physician assistants, and hospital pharmacists.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from bioMérieux.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 1/22/21